Adial Pharmaceuticals, Inc. Operating Lease, Payments
Adial Pharmaceuticals, Inc. (ADIL) reported Operating Lease, Payments of $18.02 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-12.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2023-05-12
- Adial Pharmaceuticals, Inc. operating lease, payments for the quarter ending 2023-03-31 was $18.02K, a 2.34% increase year-over-year.
- Adial Pharmaceuticals, Inc. operating lease, payments for the quarter ending 2022-12-31 was $17.61K, a 22.00% decline year-over-year.
- Adial Pharmaceuticals, Inc. operating lease, payments for the quarter ending 2022-09-30 was $17.61K, a 55.99% increase year-over-year.
- Adial Pharmaceuticals, Inc. operating lease, payments for the quarter ending 2022-06-30 was $17.38K, a 25.94% decline year-over-year.
- Adial Pharmaceuticals, Inc. operating lease, payments for fiscal 2022 was $70.20K, a 3.67% increase from fiscal 2021.
- Adial Pharmaceuticals, Inc. operating lease, payments for fiscal 2021 was $67.72K.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2023-03-31 | $18.02K 10-Q · filed 2023-05-12 | $35.63K derived: sum of 2 quarters · filed 2023-05-12 | $53.23K derived: sum of 3 quarters · filed 2023-05-12 | $70.61K derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-12-31 | $17.61K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $35.21K derived: sum of 2 quarters · filed 2023-03-30 | $52.60K derived: sum of 3 quarters · filed 2023-03-30 | $70.20K 10-K · filed 2023-03-30 |
| 2022-09-30 | $17.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $34.99K derived: sum of 2 quarters · filed 2022-11-14 | $52.59K 10-Q · filed 2022-11-14 | $75.17K derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-06-30 | $17.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $34.99K 10-Q · filed 2022-08-15 | $57.56K derived: sum of 3 quarters · filed 2023-05-12 | $68.85K derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-03-31 | $17.61K 10-Q · filed 2023-05-12 | $40.18K derived: sum of 2 quarters · filed 2023-05-12 | $51.47K derived: sum of 3 quarters · filed 2023-05-12 | $74.94K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $22.57K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $33.86K derived: sum of 2 quarters · filed 2023-03-30 | $57.33K derived: sum of 3 quarters · filed 2023-03-30 | $67.72K 10-K · filed 2023-03-30 |
| 2021-09-30 | $11.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $34.76K derived: sum of 2 quarters · filed 2022-11-14 | $45.15K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $23.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $33.86K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $10.39K 10-Q · filed 2022-05-16 | |||
| 2020-03-31 | $10.39K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |